Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F13%3A00424353" target="_blank" >RIV/61388971:_____/13:00424353 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1038/cdd.2013.60" target="_blank" >http://dx.doi.org/10.1038/cdd.2013.60</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/cdd.2013.60" target="_blank" >10.1038/cdd.2013.60</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines

Popis výsledku v původním jazyce

Immunogenic cell death induced by cytotoxic compounds contributes to the success of selected chemotherapies by eliciting a protective anticancer immune response, which is mediated by CD4(+) and CD8(+) T cells producing interferon-gamma. In many instances, cancer progression is associated with high titers of tumor-specific antibodies, which become detectable in the serum, but whose functional relevance is elusive. Here, we explored the role of humoral immune responses in the anticancer efficacy of anthracyclines. Chemotherapy reduced the number of tumor-infiltrating B cells, and failed to promote humoral responses against immunodominant tumor antigens. Although anthracycline-based anticancer chemotherapies failed in T cell-deficient mice, they successfully reduced the growth of cancers developing in mice lacking B lymphocytes (due to the injection of a B-cell-depleting anti-CD20 antibody), immunoglobulins (Igs) or Ig receptors (Fc receptor) due to genetic manipulations. These results su

Název v anglickém jazyce

Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines

Popis výsledku anglicky

Immunogenic cell death induced by cytotoxic compounds contributes to the success of selected chemotherapies by eliciting a protective anticancer immune response, which is mediated by CD4(+) and CD8(+) T cells producing interferon-gamma. In many instances, cancer progression is associated with high titers of tumor-specific antibodies, which become detectable in the serum, but whose functional relevance is elusive. Here, we explored the role of humoral immune responses in the anticancer efficacy of anthracyclines. Chemotherapy reduced the number of tumor-infiltrating B cells, and failed to promote humoral responses against immunodominant tumor antigens. Although anthracycline-based anticancer chemotherapies failed in T cell-deficient mice, they successfully reduced the growth of cancers developing in mice lacking B lymphocytes (due to the injection of a B-cell-depleting anti-CD20 antibody), immunoglobulins (Igs) or Ig receptors (Fc receptor) due to genetic manipulations. These results su

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

<a href="/cs/project/GA13-14608S" target="_blank" >GA13-14608S: Analýza detailní specificity, heterogenity a úlohy antikalretikulinových protilátek u onkologických a autoimunitních chorob.</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cell Death and Differentiation

ISSN

1350-9047

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

50-58

Kód UT WoS článku

000328622100007

EID výsledku v databázi Scopus

—